Study of Lenacapavir Taken Twice a Year for HIV Pre-Exposure Prophylaxis (PrEP)

Key Inclusion Criteria:

• Able to comprehend and provide a signed written informed consent, which must beobtained prior to initiation of study procedures.

• Cisgender men who have sex with men, transgender women, transgender men, cisgenderwomen, and nonbinary people.

• Increased likelihood of HIV acquisition as indicated by at least one of thefollowing:

1. Condomless sex with ≥ 2 partners in the past 6 months

2. Diagnosis of a bacterial sexually transmitted infection (STI) in the past 12months

3. Engagement in sex work or transactional sex in the past 12 months

4. Use of ≥ 2 courses of nonoccupational HIV post-exposure prophylaxis (nPEP) inthe past 12 months

5. Condomless sex with a partner living with HIV who has unknown or unsuppressedviral load (≥ 200 copies/mL) in the past 12 months

• Negative local rapid HIV-1/2 antibody (Ab)/antigen (Ag) test, central HIV-1/2 Ab/Ag,and HIV-1 RNA quantitative nucleic acid amplification testing (NAAT) at screening.

1. If rapid HIV-1/2 Ab/Ag tests are unavailable due to extenuating circumstances,sites may run a laboratory-instrumented HIV-1/2 Ab/Ag test at their locallaboratory, only if they confirm this is a fourth-generation assay and the timefrom blood draw to injection at any injection visit is < 48 hours.

• Estimated glomerular filtration rate (GFR) at least 60 mL/min at screening accordingto the Cockcroft-Gault formula for creatinine clearance (CLcr):

• (140 - age in years) × (weight in kg) x (0.85 if female) = CLcr (mL/min) / 72 × (serum creatinine in mg/dL)

Key Exclusion Criteria:

• Coenrollment in any other clinical study (including observational) without priorapproval from the sponsor is prohibited while participating in this study.

• Known hypersensitivity to the study drug, the metabolites, or formulation excipient.

• Current use of PrEP, defined as the use of PrEP in the preceding 4 weeks. PrEPshould not be discontinued to facilitate study participation. For cabotegravir, thisis defined as 4 weeks since the next injection was due (ie, 12 weeks since theirmost recent cabotegravir injection).

• Current use of nPEP, unless the prescribed course will be completed prior torandomization.

• Past or current participation in HIV vaccine or HIV broadly neutralizing Ab studyunless participant provides documentation of receipt of placebo (ie, not activeproduct).

• Acute viral hepatitis A, B, or C or evidence of chronic hepatitis B or C infection

• Severe hepatic impairment or a history of or current clinical decompensated livercirrhosis (eg, ascites, encephalopathy, variceal bleeding).

• Have a suspected or known active, serious infection(s) (eg, active tuberculosis,etc).

Note: Other protocol defined Inclusion/Exclusion criteria may apply